Advanced in Angiosarcoma

Dr. Ryan F. Porter

Hematology Oncology | Hematology | Oncology
Dean Health Systems Inc
515 22nd Ave, 
Monroe, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
17 Years of Experience
Advanced in Angiosarcoma
Dean Health Systems Inc
515 22nd Ave, 
Monroe, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ryan Porter is a Hematologist Oncology specialist and a Hematologist in Monroe, Wisconsin. Dr. Porter has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Familial Prostate Cancer, Familial Pancreatic Cancer, Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin, 2008
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Ssm Health St Mary's Hospital - Janesville
Ssm Health St Mary's Hospital - Madison
Ssm Health St Clare Hospital - Baraboo
Fort Memorial Hospital
Upland Hills Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

DEAN HEALTH SYSTEMS INC
515 22nd Ave, Monroe, WI 53566
Other Locations
DEAN HEALTH SYSTEMS INC
833 S Iowa St, Suite 102, Dodgeville, WI 53533
DEAN HEALTH SYSTEMS INC
700 S Park St, Suite A, Madison, WI 53715
DEAN HEALTH SYSTEMS INC
752 N High Point Rd, Madison, WI 53717
DEAN HEALTH SYSTEMS INC
2825 Hunters Trl, Portage, WI 53901
DEAN HEALTH SYSTEMS INC
3200 E Racine St, Janesville, WI 53546
DEAN HEALTH SYSTEMS INC
11101 N Sherman Rd, Edgerton, WI 53534
DEAN HEALTH SYSTEMS INC
10 Tower Dr, Sun Prairie, WI 53590
DEAN HEALTH SYSTEMS INC
1515 Park Ave, Columbus, WI 53925
DEAN HEALTH SYSTEMS INC
740 Reena Ave, Fort Atkinson, WI 53538
DEAN HEALTH SYSTEMS INC
1110 N Main St, Edgerton, WI 53534
DEAN HEALTH SYSTEMS INC
103 Lake St, Deerfield, WI 53531
DEAN HEALTH SYSTEMS INC
753 N Main St, Oregon, WI 53575
DEAN HEALTH SYSTEMS INC
1305 W Main St, Whitewater, WI 53190
DEAN HEALTH SYSTEMS INC
1821 S Stoughton Rd, Madison, WI 53716
DEAN HEALTH SYSTEMS INC
225 Church St, Stoughton, WI 53589

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 8 Less Clinical Trials

2 Total Publications

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Journal: Haematologica
Published: July 10, 2023
Similar Doctors
Distinguished in Angiosarcoma
Dr. Amy L. Stella
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Amy L. Stella
Hematology Oncology | Hematology | Oncology

Dean Health Systems Inc

3200 E Racine St, 
Janesville, WI 
 (33.6 miles away)
608-371-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amy Stella is a Hematologist Oncology specialist and a Hematologist in Janesville, Wisconsin. Dr. Stella is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Stella is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Rubina D. Qamar
Hematology Oncology | Oncology | Hematology
Distinguished in Angiosarcoma
Dr. Rubina D. Qamar
Hematology Oncology | Oncology | Hematology

University Of Wisconsin Medical Foundation Inc

1400 E Side Rd, 
Platteville, WI 
 (42.6 miles away)
608-348-2331
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rubina Qamar is a Hematologist Oncology specialist and an Oncologist in Platteville, Wisconsin. Dr. Qamar is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Tissue Biopsy. Dr. Qamar is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Arshad R. Shaikh
Hematology Oncology | Hospital Medicine | Hematology
Distinguished in Angiosarcoma
Dr. Arshad R. Shaikh
Hematology Oncology | Hospital Medicine | Hematology

Freeport Memorial Hospital

1163 W Stephenson St, 
Freeport, IL 
 (21.6 miles away)
815-599-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arshad Shaikh is a Hematologist Oncology specialist and a Hospital Medicine provider in Freeport, Illinois. Dr. Shaikh is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Severe Congenital Neutropenia, Angiosarcoma, Inflammatory Breast Cancer, and Chronic Familial Neutropenia. Dr. Shaikh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Porter's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 81 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile